Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;136(Pt 1):259-68.
doi: 10.1093/brain/aws309.

Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database

Affiliations

Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database

Günther Metz et al. Brain. 2013 Jan.

Abstract

The aim of this cross-sectional study was to analyse disease progression in Friedreich's ataxia as measured by the International Cooperative Ataxia Rating Scale. Single ratings from 603 patients with Friedreich's ataxia were analysed as a function of disease duration, age of onset and GAA repeat lengths. The relative contribution of items and subscales to the total score was studied as a function of disease progression. In addition, the scaling properties were assessed using standard statistical measures. Average total scale progression per year depends on the age of disease onset, the time since diagnosis and the GAA repeat length. The age of onset inversely correlates with increased GAA repeat length. For patients with an age of onset ≤14 years associated with a longer repeat length, the average yearly rate of decline was 2.5 ± 0.18 points in the total International Cooperative Ataxia Rating Scale for the first 20 years of disease duration, whereas patients with a later onset progress more slowly (1.8 ± 0.27 points/year). Ceiling effects in posture, gait and lower limb scale items lead to a reduced sensitivity of the scale in the severely affected population with a total score of >60 points. Psychometric scaling analysis shows generally favourable properties for the total scale, but the subscale grouping could be improved. This cross-sectional study provides a detailed characterization of the International Cooperative Ataxia Rating Scale. The analysis further provides rates of change separated for patients with early and late disease onset, which is driven by the GAA repeat length. Differences in the subscale dynamics merit consideration in the design of future clinical trials applying this scale as a neurological assessment instrument in Friedreich's ataxia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scatter plot of ICARS rating versus age at assessment (A) and disease duration (B). Mean values are indicated as dashed lines. There are 603 patients represented in A whereas disease duration data were available for only 529 patients in B.
Figure 2
Figure 2
(A) Total ICARS is plotted against disease duration (up to 20 years: black circles and straight line fit; >20 years: grey diamonds) separated for subgroup of patients <14 years of age at the time of diagnosis (left, n = 327) or >14 years (right, n = 202). (B) The mean ICARS is shown over disease duration grouped into 5-year intervals, coloured by data source.
Figure 3
Figure 3
Age of onset (on the left y-axis) is plotted against GAA triplet repeat length of the shorter allele (filled grey circles) for 389 patients with Friedreich’s ataxia for which both age of onset and repeat length were available. Patients were grouped in ranges of 200 repeats starting from 0–200 up to >800, and the ICARS annual rate of change (right y-axis) in these groups is plotted as black squares connected by a line. The vertical dashed line indicates the median repeat length of 700, and the horizontal dashed line indicates an age of disease onset of 14 years (see subgroup analysis in Tables 1 and 2).
Figure 4
Figure 4
Heat map representing the individual item scores from lowest score (green) to maximum score (red) for each of the 19 ICARS scale items. The actual test represented by individual ICARS item numbers can be looked up in Supplementary Table 1 or in Trouillas 1997. x-axis: data are displayed as 20 bins of 5.0 points across the total ICARS range. y-axis: proportion of patients within each bin reaching minimum (green), maximum (red) or intermediate item scores (green-red color spectrum). KF = kinetic functions; OD = oculomotor disorders; PG = posture and gait disturbances; SD = speech disorders.
Figure 5
Figure 5
The mean ICARS item as a function of total ICARS is plotted in groups corresponding to the four ICARS subscales. The actual test represented by individual ICARS item numbers can be looked up in Supplementary Table 1 or in Trouillas 1997. x-axis: data are displayed as 20 bins across the total 100 point ICARS range. y-axis: mean item value per bin. KF = kinetic functions; OD = oculomotor disorders; PG = posture and gait disturbances; SD = speech disorders.

References

    1. Arnold P, Boulat O, Maire R, Kuntzer T. Expanding view of phenotype and oxidative stress in Friedreich's ataxia patients with and without idebenone. Schweiz Arch Neurol Psychiatr. 2006;157:169–76.
    1. Burk K, Malzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hubsch T, et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA) Mov Disord. 2009;24:1779–84. - PubMed
    1. Cano SJ, Hobart JC, Hart PE, Korlipara LV, Schapira AH, Cooper JM. International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia? Mov Disord. 2005;20:1585–91. - PubMed
    1. Delatycki MB. Evaluating the progression of Friedreich ataxia and its treatment. J Neurol. 2009;256(Suppl 1):36–41. - PubMed
    1. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6:878–86. - PubMed

Publication types